Biotherapies in inflammatory ocular disorders: Interferons, immunoglobulins, monoclonal antibodies

Autoimmunity Reviews

Volumn 12, Issue 7, 2013, Pages 774-783

  Saadoun, D ^a   Bodaghi, B ^b   Bienvenu, B ^c   Wechsler, B ^a   Sene, D ^d   Trad, S ^e   Abad, S ^f   Cacoub, P ^a   Kodjikian, L ^g,h   Seve P ^g,h  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c CAEN UNIVERSITY HOSPITAL   (France)

^d HÔPITAL LARIBOISIÈRE   (France)

^e CHU Ambroise Pare   (France)

^f AVICENNE HOSPITAL   (France)

^g HOSPICES CIVILS DE LYON   (France)

^h UNIVERSITÉ DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; AZATHIOPRINE; BETA1A INTERFERON; CLAIRYG; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXCHLORPHENIRAMINE MALEATE; ETANERCEPT; GEVOKIZUMAB; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INFLIXIMAB; INTERFERON; METHOTREXATE; MONOCLONAL ANTIBODY; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; PREDNISONE; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; STEROID; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ALOPECIA; ANAPHYLAXIS; ANXIETY DISORDER; ARTERY THROMBOSIS; ARTHRALGIA; ASEPTIC MENINGITIS; AUTOIMMUNE UVEITIS; BACKACHE; BEHCET DISEASE; BIOLOGICAL THERAPY; BIRDSHOT DISEASE; BIRDSHOT RETINOCHOROIDOPATHY; BLINDNESS; BRONCHOSPASM; CELLULITIS; CHILL; CLINICAL TRIAL (TOPIC); COUGHING; CYTOPENIA; DEPRESSION; DERMATOMYOSITIS; DIABETES MELLITUS; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG BIOAVAILABILITY; DRUG DIFFUSION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; DYSPNEA; EYE DISEASE; EYE INFLAMMATION; FATIGUE; FEVER; FLU LIKE SYNDROME; FLUSHING; GRANULOMATOSIS WITH POLYANGIITIS; HEADACHE; HEART ARRHYTHMIA; HEART FAILURE; HEMOLYTIC ANEMIA; HEPATITIS B; HEPATITIS C; HUMAN; HYPERTENSION; INFECTION; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; KERATOCONJUNCTIVITIS; KIDNEY FAILURE; LEUKOENCEPHALOPATHY; LEUKOPENIA; LIVER DYSFUNCTION; LUPUS ERYTHEMATOSUS; LUPUS LIKE SYNDROME; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MENTAL DISEASE; MUCOUS MEMBRANE PEMPHIGOID; MULTIPLE SCLEROSIS; MYALGIA; NAIL DYSTROPHY; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHUMAN; OCULAR CICATRICIAL PEMPHIGOID; OPPORTUNISTIC INFECTION; OPTIC NEURITIS; ORBITAL MYOSITIS; PEMPHIGOID; PLASMA CELL GRANULOMA; PNEUMONIA; PRIMARY INTRAOCULAR LYMPHOMA; PROSPECTIVE STUDY; PRURITUS; PSORIASIS; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REMISSION; RETINA MACULA CYSTOID EDEMA; RETINA MACULA EDEMA; RETINA VASCULITIS; RETINA VEIN OCCLUSION; RETINOPATHY; RETROSPECTIVE STUDY; REVIEW; SARCOIDOSIS; SCLERITIS; SEIZURE; SEPTICEMIA; SERPIGINOUS CHOROIDITIS; SIDE EFFECT; SJOEGREN SYNDROME; SUBRETINAL NEOVASCULARIZATION; SUICIDE ATTEMPT; SUSAC SYNDROME; SYMBLEPHARON; SYMPATHIC OPHTHALMIA; THORAX PAIN; THROAT IRRITATION; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; UVEITIS; VEIN THROMBOSIS; VISUAL ACUITY; VOGT KOYANAGI HARADA; WEGENER GRANULOMATOSIS; XEROPHTHALMIA;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL THERAPY; EYE DISEASES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFLAMMATION; INTERFERONS;

EID: 84877794226     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.02.002     Document Type: Review

References (86)

1. Jabs D.A., Rosenbaum J.T. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2001, 131(5):679.
2. Heiligenhaus A., Thurau S., Hennig M., Grajewski R.S., Wildner G. Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease. Graefes Arch Clin Exp Ophthalmol 2010, 248(11):1531-1551.
3. Buggage R.R., Levy-Clarke G., Sen H.N., Ursea R., Srivastava S.K., Suhler E.B., et al. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behcet's disease. Ocul Immunol Inflamm 2007, 15(2):63-70.
4. Lequerre T., Quartier P., Rosellini D., Alaoui F., De Bandt M., Mejjad O., et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 2008, 67(3):302-308.
5. Vounotrypidis P., Sakellariou G.T., Zisopoulos D., Berberidis C. Refractory relapsing polychondritis: rapid and sustained response in the treatment with an IL-1 receptor antagonist (anakinra). Rheumatology (Oxford) 2006, 45(4):491-492.
6. Gul A., Tugal-Tutkun I., Dinarello C.A., Reznikov L., Esen B.A., Mirza A., et al. Interleukin-1beta-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study. Ann Rheum Dis 2012, 71(4):563-566.
7. Kaly L., Rosner I. Tocilizumab - a novel therapy for non-organ-specific autoimmune diseases. Best Pract Res Clin Rheumatol 2012, 26(1):157-165.
8. Greco A., Gallo A., Fusconi M., Magliulo G., Turchetta R., Marinelli C., et al. Cogan's syndrome: an autoimmune inner ear disease. Autoimmun Rev 2013, 12(3):396-400.
9. Yoshimura T., Sonoda K.H., Ohguro N., Ohsugi Y., Ishibashi T., Cua D.J., et al. Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology (Oxford) 2009, 48(4):347-354.
10. Haruta H., Ohguro N., Fujimoto M., Hohki S., Terabe F., Serada S., et al. Blockade of interleukin-6 signaling suppresses not only Th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 2011, 52(6):3264-3271.
11. Muselier A., Bielefeld P., Bidot S., Vinit J., Besancenot J.F., Bron A. Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. Ocul Immunol Inflamm 2011, 19(5):382-383.
12. Hirano T., Ohguro N., Hohki S., Hagihara K., Shima Y., Narazaki M., et al. A case of Behcet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol 2012, 22(2):298-302.
13. Tappeiner C., Heinz C., Ganser G., Heiligenhaus A. Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis?. J Rheumatol 2012, 39(6):1294-1295.
14. Caorsi R., Federici S., Gattorno M. Biologic drugs in autoinflammatory syndromes. Autoimmun Rev 2012, 12(1):81-86.
15. Derevjanik N.L., Vinores S.A., Xiao W.H., Mori K., Turon T., Hudish T., et al. Quantitative assessment of the integrity of the blood-retinal barrier in mice. Invest Ophthalmol Vis Sci 2002, 43(7):2462-2467.
16. Rodrigues E.B., Farah M.E., Maia M., Penha F.M., Regatieri C., Melo G.B., et al. Therapeutic monoclonal antibodies in ophthalmology. Prog Retin Eye Res 2009, 28(2):117-144.
17. Bodaghi B., Bui Quoc E., Wechsler B., Tran T.H., Cassoux N., Le Thi Huong D., et al. Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors. Ann Rheum Dis 2005, 64(6):962-964.
18. Niccoli L., Nannini C., Benucci M., Chindamo D., Cassara E., Salvarani C., et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study. Rheumatology (Oxford) 2007, 46(7):1161-1164.
19. Tugal-Tutkun I., Guney-Tefekli E., Urgancioglu M. Results of interferon-alfa therapy in patients with Behcet uveitis. Graefes Arch Clin Exp Ophthalmol 2006, 244(12):1692-1695.
20. Tognon S., Graziani G., Marcolongo R. Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects. Ann N Y Acad Sci 2007, 1110:474-484.
21. Arida A., Fragiadaki K., Giavri E., Sfikakis P.P. Anti-TNF agents for Behcet's disease: analysis of published data on 369 patients. Semin Arthritis Rheum 2011, 41(1):61-70.
22. Markomichelakis N.N., Theodossiadis P.G., Pantelia E., Papaefthimiou S., Theodossiadis G.P., Sfikakis P.P. Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol 2004, 138(4):648-650.
23. Giansanti F., Barbera M.L., Virgili G., Pieri B., Emmi L., Menchini U. Infliximab for the treatment of posterior uveitis with retinal neovascularization in Behcet disease. Eur J Ophthalmol 2004, 14(5):445-448.
24. Petropoulos I.K., Vaudaux J.D., Guex-Crosier Y. Anti-TNF-alpha therapy in patients with chronic non-infectious uveitis: the experience of Jules Gonin Eye Hospital. Klin Monbl Augenheilkd 2008, 225(5):457-461.
25. Diaz-Llopis M., Garcia-Delpech S., Salom D., Udaondo P., Hernandez-Garfella M., Bosch-Morell F., et al. Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther 2008, 24(3):351-361.
26. Galor A., Perez V.L., Hammel J.P., Lowder C.Y. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006, 113(12):2317-2323.
27. Diaz-Llopis M., Salom D., Garcia-de-Vicuna C., Cordero-Coma M., Ortega G., Ortego N., et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology 2012, 119(8):1575-1581.
28. Suhler E.B., Lowder C.Y., Goldstein D.A., Giles T., Lauer A.K., Kurz P.A., et al. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. Br J Ophthalmol 2013, [Electronic publication ahead of print].
29. Doctor P., Sultan A., Syed S., Christen W., Bhat P., Foster C.S. Infliximab for the treatment of refractory scleritis. Br J Ophthalmol 2010, 94(5):579-583.
30. Zannin M.E., Birolo C., Gerloni V.M., Miserocchi E., Pontikaki I., Paroli M.P., et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian registry. J Rheumatol 2013, 40(1):74-79.
31. Simonini G., Taddio A., Cattalini M., Caputo R., De Libero C., Naviglio S., et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res (Hoboken) 2011, 63(4):612-618.
32. Artornsombudh P., Gevorgyan O., Payal A., Siddique S.S., Foster C.S. Infliximab treatment of patients with birdshot retinochoroidopathy. Ophthalmology 2012, [Electronic publication ahead of print].
33. Baughman R.P., Lower E.E., Bradley D.A., Raymond L.A., Kaufman A. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 2005, 128:1062-1067.
34. Maneiro J.R., Salgado E., Gomez-Reino J.J., Carmona L. Efficacy and safety of TNF antagonists in sarcoidosis: data from the Spanish registry of biologics BIOBADASER and a systematic review. Semin Arthritis Rheum 2012, 42(1):89-103.
35. Erckens R.J., Mostard R.L., Wijnen P.A., Schouten J.S., Drent M. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol 2012, 250(5):713-720.
36. Wendling D., Paccou J., Berthelot J.M., Flipo R.M., Guillaume-Czitrom S., Prati C., et al. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum 2011, 41(3):503-510.
37. Baraliakos X., van den Berg R., Braun J., van der Heijde D. Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis. Rheumatology (Oxford) 2012, 51(8):1378-1387.
38. Yao Y., Liu Z., Jallal B., Shen N., Ronnblom L. Type I interferons in Sjogren's syndrome. Autoimmun Rev 2013, 12:558-566.
39. Lim J.H., Lee Y.N., Kim Y.S., Kim S.G., Jeong S.W., Jang J.Y., et al. Vogt-Koyanagi-Harada disease occurring during pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C. Korean J Hepatol 2011, 17(1):61-65.
40. Tsambaos D., Eichelberg D., Goos M. Behcet's syndrome: treatment with recombinant leukocyte alpha-interferon. Arch Dermatol Res 1986, 278(4):335-336.
41. Alpsoy E., Durusoy C., Yilmaz E., Ozgurel Y., Ermis O., Yazar S., et al. Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 2002, 138(4):467-471.
42. Hazirolan D., Stubiger N., Pleyer U. Light on the Horizont: biologicals in Behcet uveitis. Acta Ophthalmol 2012, [Electronic publication ahead of print].
43. Deuter C., Stubiger N., Zierhut M. Interferon-alpha therapy in noninfectious uveitis. Dev Ophthalmol 2012, 51:90-97.
44. Hatemi G., Silman A., Bang D., Bodaghi B., Chamberlain A.M., Gul A., et al. Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease. Ann Rheum Dis 2009, 68(10):1528-1534.
45. Deuter C.M., Koetter I., Guenaydin I., Stuebiger N., Zierhut M. Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina 2006, 26(7):786-791.
46. Butler N.J., Suhler E.B., Rosenbaum J.T. Interferon alpha 2b in the treatment of uveitic cystoid macular edema. Ocul Immunol Inflamm 2012, 20(2):86-90.
47. Bodaghi B., Gendron G., Wechsler B., Terrada C., Cassoux N., Huong du L.T., et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 2007, 91(3):335-339.
48. Plskova J., Greiner K., Forrester J.V. Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol 2007, 144(1):55-61.
49. Becker M.D., Heiligenhaus A., Hudde T., Storch-Hagenlocher B., Wildemann B., Barisani-Asenbauer T., et al. Interferon as a treatment for uveitis associated with multiple sclerosis. Br J Ophthalmol 2005, 89(10):1254-1257.
50. Atzeni F., Benucci M., Salli S., Bongiovanni S., Boccassini L., Sarzi-Puttini P. Different effects of biological drugs in rheumatoid arthritis. Autoimmun Rev 2013, 12(5):575-579.
51. Atzeni F., Talotta R., Benucci M., Salaffi F., Cassinotti A., Varisco V., et al. Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun Rev 2012, [Electronic publication ahead of print].
52. Epis O.M., Giacomelli L., Deidda S., Bruschi E. Tight control applied to the biological therapy of rheumatoid arthritis. Autoimmun Rev 2012, [Electronic publication ahead of print].
53. Molloy E.S., Calabrese L.H. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum 2012, 64(9):3043-3051.
54. Heiligenhaus A., Miserocchi E., Heinz C., Gerloni V., Kotaniemi K. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology (Oxford) 2011, 50(8):1390-1394.
55. Miserocchi E., Pontikaki I., Modorati G., Gattinara M., Meroni P.L., Gerloni V. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimmun Rev 2011, 11(1):35-39.
56. Alexeeva E.I., Valieva S.I., Bzarova T.M., Semikina E.L., Isaeva K.B., Lisitsyn A.O., et al. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin Rheumatol 2011, 30(9):1163-1172.
57. Davatchi F., Shams H., Rezaipoor M., Sadeghi-Abdollahi B., Shahram F., Nadji A., et al. Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study). Int J Rheum Dis 2010, 13(3):246-252.
58. Pakrou N., Selva D., Leibovitch I. Wegener's granulomatosis: ophthalmic manifestations and management. Semin Arthritis Rheum 2006, 35(5):284-292.
59. Stone J.H., Merkel P.A., Spiera R., Seo P., Langford C.A., Hoffman G.S., et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010, 363(3):221-232.
60. Aries P.M., Hellmich B., Voswinkel J., Both M., Nolle B., Holl-Ulrich K., et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006, 65(7):853-858.
61. Taylor S.R., Salama A.D., Joshi L., Pusey C.D., Lightman S.L. Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum 2009, 60(5):1540-1547.
62. Holle J.U., Dubrau C., Herlyn K., Heller M., Ambrosch P., Noelle B., et al. Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis 2012, 71(3):327-333.
63. Ramos-Casals M., Tzioufas A.G., Stone J.H., Siso A., Bosch X. Treatment of primary Sjogren syndrome: a systematic review. JAMA 2010, 304(4):452-460.
64. Ahmadi-Simab K., Lamprecht P., Nolle B., Ai M., Gross W.L. Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab. Ann Rheum Dis 2005, 64(7):1087-1088.
65. Taoka K., Yamamoto G., Kaburaki T., Takahashi T., Araie M., Kurokawa M. Treatment of primary intraocular lymphoma with rituximab, high dose methotrexate, procarbazine, and vincristine chemotherapy, reduced whole-brain radiotherapy, and local ocular therapy. Br J Haematol 2012, 157(2):252-254.
66. Foster C.S., Chang P.Y., Ahmed A.R. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. Ophthalmology 2010, 117(5):861-869.
67. Miserocchi E., Modorati G. Rituximab for noninfectious uveitis. Dev Ophthalmol 2012, 51:98-109.
68. Kaveri S.V. Intravenous immunoglobulin: exploiting the potential of natural antibodies. Autoimmun Rev 2012, 11(11):792-794.
69. Maddur M.S., Kaveri S.V., Bayry J. Comparison of different IVIg preparations on IL-17 production by human Th17 cells. Autoimmun Rev 2011, 10(12):809-810.
70. Ruffatti A., Marson P., Svaluto-Moreolo G., Marozio L., Tibaldi M., Favaro M., et al. A combination therapy protocol of plasmapheresis, intravenous immunoglobulins and betamethasone to treat anti-Ro/La-related congenital atrioventricular block. A case series and review of the literature. Autoimmun Rev 2013, [Electronic publication ahead of print].
71. Djoumerska-Alexieva I., Pashova S., Vassilev T., Pashov A. The protective effect of modified intravenous immunoglobulin in LPS sepsis model is associated with an increased IRA B cells response. Autoimmun Rev 2012, [Electronic publication ahead of print].
72. Rogosnitzky M., Danks R., Holt D. Intravenous immunoglobulin for the treatment of Crohn's disease. Autoimmun Rev 2012, 12(2):275-280.
73. Cousens L.P., Tassone R., Mazer B.D., Ramachandiran V., Scott D.W., De Groot A.S. Tregitope update: mechanism of action parallels IVIg. Autoimmun Rev 2013, 12(3):436-443.
74. Marie I., Maurey G., Herve F., Hellot M.F., Levesque H. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature. Br J Dermatol 2006, 155(4):714-721.
75. Cassoux N., Goichot-Bonnat L., Karmochkine M., Georges F., Kullmann N., Lehoang P., et al. Efficacy of intravenous immunoglobulin in the treatment of Birdshot retinochoroiditis. J Fr Ophtalmol 2002, 25(1):23-30.
76. Tellier Z. Human immunoglobulins in intraocular inflammation. Ann N Y Acad Sci 2007, 1110:337-347.
77. Rosenbaum J.T., George R.K., Gordon C. The treatment of refractory uveitis with intravenous immunoglobulin. Am J Ophthalmol 1999, 127(5):545-549.
78. Tselis A., Perumal J., Caon C., Hreha S., Ching W., Din M., et al. Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin. Eur J Neurol 2008, 15(11):1163-1167.
79. Wiwatwongwana D., Esdaile J.M., White V.A., Dolman P.J. Intravenous immunoglobulin (IVIG) for orbital Wegener's granulomatosis. Can J Ophthalmol 2012, 47(1):82-83.
80. Mateen F.J., Zubkov A.Y., Muralidharan R., Fugate J.E., Rodriguez F.J., Winters J.L., et al. Susac syndrome: clinical characteristics and treatment in 29 new cases. Eur J Neurol 2012, 19(6):800-811.
81. Kotter I., Zierhut M., Eckstein A.K., Vonthein R., Ness T., Gunaydin I., et al. Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003, 87(4):423-431.
82. Gueudry J., Wechsler B., Terrada C., Gendron G., Cassoux N., Fardeau C., et al. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behcet disease. Am J Ophthalmol 2008, 146(6):837-44 e1.
83. Krause L., Altenburg A., Pleyer U., Kohler A.K., Zouboulis C.C., Foerster M.H. Longterm visual prognosis of patients with ocular Adamantiades-Behcet's disease treated with interferon-alpha-2a. J Rheumatol 2008, 35(5):896-903.
84. Sobaci G., Erdem U., Durukan A.H., Erdurman C., Bayer A., Koksal S., et al. Safety and effectiveness of interferon alpha-2a in treatment of patients with Behcet's uveitis refractory to conventional treatments. Ophthalmology 2010, 117(7):1430-1435.
85. Deuter C.M., Zierhut M., Mohle A., Vonthein R., Stobiger N., Kotter I. Long-term remission after cessation of interferon-alpha treatment in patients with severe uveitis due to Behcet's disease. Arthritis Rheum 2010, 62(9):2796-2805.
86. Onal S., Kazokoglu H., Koc A., Akman M., Bavbek T., Direskeneli H., et al. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behcet uveitis. Arch Ophthalmol 2011, 129(3):288-294.